TSCAN THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.87 USD | -0.34% |
|
+13.71% | +50.77% |
| May. 13 | Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target | MT |
| May. 13 | TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 106.9 | 37.32 | 278.8 | 508.5 | - | - |
| Enterprise Value (EV) 1 | -54.48 | -53.41 | 116.8 | 439.6 | 441.8 | 508.5 |
| P/E ratio | -1.08 x | -0.56 x | -4.29 x | -7.24 x | -6.74 x | -6.58 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 10.5 x | 2.76 x | 13.2 x | 417 x | 68.6 x | 73 x |
| EV / Revenue | -5.37 x | -3.95 x | 5.55 x | 360 x | 59.6 x | 73 x |
| EV / EBITDA | 1.27 x | 0.94 x | -1.41 x | -4.07 x | -3.41 x | - |
| EV / FCF | 0.93 x | 0.76 x | -1.81 x | -4.67 x | -3.98 x | -4.3 x |
| FCF Yield | 108% | 132% | -55.2% | -21.4% | -25.1% | -23.3% |
| Price to Book | - | 0.37 x | 1.85 x | 6.05 x | 10.3 x | - |
| Nbr of stocks (in thousands) | 23,761 | 24,080 | 47,825 | 57,139 | - | - |
| Reference price 2 | 4.500 | 1.550 | 5.830 | 8.900 | 8.900 | 8.900 |
| Announcement Date | 3/9/22 | 3/8/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 10.14 | 13.54 | 21.05 | 1.22 | 7.412 | 6.964 |
| EBITDA 1 | - | -42.8 | -56.95 | -82.89 | -108.1 | -129.5 | - |
| EBIT 1 | - | -48.64 | -66.64 | -93.46 | -130.4 | -145.7 | -158.4 |
| Operating Margin | - | -479.65% | -492.32% | -444% | -10,691.04% | -1,965.79% | -2,274.33% |
| Earnings before Tax (EBT) 1 | - | -48.62 | -66.22 | -89.22 | -140 | -160 | -180 |
| Net income 1 | -26.13 | -48.62 | -66.22 | -89.22 | -130.6 | -150.8 | -161.6 |
| Net margin | - | -479.49% | -489.26% | -423.86% | -10,705.76% | -2,034.76% | -2,320.5% |
| EPS 2 | -3.480 | -4.170 | -2.750 | -1.360 | -1.230 | -1.320 | -1.352 |
| Free Cash Flow 1 | - | -58.62 | -70.73 | -64.5 | -94.08 | -111 | -118.4 |
| FCF margin | - | -578.03% | -522.56% | -306.45% | -7,711.61% | -1,497.69% | -1,699.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/19/21 | 3/9/22 | 3/8/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.854 | 3.021 | 4.056 | 3.363 | 3.096 | 6.803 | 3.148 | 3.887 | 7.211 | 0.566 | 2.024 | 2.031 | 1.889 | 1.25 | 1.25 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -14.2 | -16.16 | -15.25 | -16.58 | -18.65 | -22.74 | -24.61 | -24.75 | -21.36 | -31.37 | -30.79 | -32.56 | -33.07 | -37.2 | -38.7 |
| Operating Margin | -497.62% | -535.02% | -375.89% | -492.95% | -602.33% | -334.31% | -781.77% | -636.69% | -296.17% | -5,542.93% | -1,521.81% | -1,603.39% | -1,751.11% | -2,976% | -3,096% |
| Earnings before Tax (EBT) 1 | -14.2 | -16.16 | -15.1 | -16.24 | -18.72 | -22.56 | -24.04 | -23 | -19.61 | -30.14 | -34.4 | -37.9 | -37.5 | -37.2 | -38.7 |
| Net income 1 | -14.2 | -16.16 | -15.1 | -16.24 | -18.72 | -22.56 | -24.04 | -23 | -19.61 | -30.14 | -31.97 | -33.91 | -34.57 | -37.2 | -38.7 |
| Net margin | -497.55% | -534.79% | -372.21% | -483.05% | -604.75% | -331.66% | -763.82% | -591.64% | -271.99% | -5,325.44% | -1,580.13% | -1,669.44% | -1,830.28% | -2,976% | -3,096% |
| EPS 2 | -0.5900 | -0.6700 | -0.6300 | -0.6700 | -0.7800 | -0.9300 | -0.5100 | -0.2400 | -0.1100 | -0.3200 | -0.2800 | -0.2960 | -0.3000 | -0.4000 | -0.4000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/22 | 5/9/22 | 8/10/22 | 11/9/22 | 3/8/23 | 5/10/23 | 8/10/23 | 11/9/23 | 3/6/24 | 5/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 161 | 90.7 | 162 | 68.9 | 66.7 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -58.6 | -70.7 | -64.5 | -94.1 | -111 | -118 |
| ROE (net income / shareholders' equity) | - | - | -50.9% | -71.3% | -84.3% | -124% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 4.130 | 3.150 | 1.470 | 0.8600 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 9.94 | 4.23 | 3.15 | 3.76 | 4.5 | 6 |
| Capex / Sales | - | 98.03% | 31.22% | 14.95% | 53.57% | 75.89% | 114.88% |
| Announcement Date | 3/19/21 | 3/9/22 | 3/8/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.9
USD
Average target price
12.5
USD
Spread / Average Target
+40.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.66% | 509M | |
| +33.37% | 50.85B | |
| +1.55% | 42.82B | |
| +49.11% | 42.03B | |
| -4.22% | 29.55B | |
| +11.57% | 26.11B | |
| -21.00% | 19.13B | |
| +7.36% | 13.05B | |
| +28.30% | 12.16B | |
| +23.80% | 12.08B |
- Stock Market
- Equities
- TCRX Stock
- Financials TScan Therapeutics, Inc.